RP2 Clinical Dataset
Ultra-Comprehensive Data Analysis Report
Table of Contents
1. Executive Summary
Total Studies: 19
Total Records: 11,236
Total Unique Biomarkers/Variables: 183
2. Complete Biomarker Catalog
This section lists EVERY biomarker and variable found across ALL studies, with complete statistics.
Hiv (3 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| CD4 Count | 1,367 | 2 | 201.67 - 633.52 | 2.00 - 1596.00 | 98.9% |
| Antiretroviral Therapy Status | 305 | 1 | N/A | N/A | 100.0% |
| PCR - HIV Viral Load Roche | 305 | 1 | 7.16 - 7.16 | 0.00 - 63.00 | 100.0% |
Haematology (14 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| HEMOGLOBIN | 1,367 | 2 | 12.80 - 13.58 | 5.40 - 20.50 | 99.1% |
| WBC | 1,367 | 2 | 4.25 - 5.44 | 1.20 - 15.85 | 99.1% |
| NEUTROPHILS | 1,367 | 2 | 2.57 - 5.70 | 0.39 - 71.10 | 99.1% |
| LYMPHOCYTES | 1,367 | 2 | 2.27 - 4.15 | 0.25 - 53.10 | 99.1% |
| PLATELET COUNT | 1,351 | 2 | 230.56 - 264.91 | 19.00 - 747.00 | 98.3% |
| HEMATOCRIT | 1,066 | 1 | 16.86 - 16.86 | 0.19 - 60.30 | 99.4% |
| Erythrocytes | 302 | 1 | 4.33 - 4.33 | 2.72 - 6.55 | 99.0% |
| MONOCYTES | 301 | 1 | 0.40 - 0.40 | 0.14 - 0.94 | 98.7% |
| EOSINOPHILS | 301 | 1 | 0.13 - 0.13 | 0.00 - 0.74 | 98.7% |
| BASOPHILS | 301 | 1 | 0.03 - 0.03 | 0.00 - 0.19 | 98.7% |
| MCV (MEAN CELL VOLUME) | 301 | 1 | 96.50 - 96.50 | 60.50 - 121.10 | 98.7% |
| Mean Cell Haemoglobin | 301 | 1 | 31.77 - 31.77 | 18.20 - 42.60 | 98.7% |
| Mean Cell Haemoglobin Concentration | 301 | 1 | 32.86 - 32.86 | 29.70 - 38.10 | 98.7% |
| RDW | 301 | 1 | 14.60 - 14.60 | 11.90 - 23.90 | 98.7% |
Uncategorized (135 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| heat_completeness | 10,180 | 10 | 0.60 - 1.00 | 0.07 - 1.00 | 100.0% |
| BMI | 3,387 | 4 | 23.80 - 1601.42 | 14.60 - 850000.00 | 98.6% |
| CD4 cell count | 2,273 | 1 | 687.85 - 687.85 | 3.00 - 9999.00 | 89.1% |
| pulse_rate | 2,129 | 1 | 72.50 - 72.50 | 43.00 - 120.00 | 100.0% |
| bmi | 2,128 | 1 | 24.98 - 24.98 | 14.00 - 40.60 | 100.0% |
| oxygen_saturation | 2,127 | 1 | 97.99 - 97.99 | 89.00 - 100.00 | 99.9% |
| respiratory_rate | 2,123 | 1 | 17.85 - 17.85 | 11.00 - 52.00 | 99.7% |
| waist circumference | 1,576 | 2 | 94.79 - 893.62 | 0.00 - 9150.00 | 85.9% |
| treatment_arm | 1,182 | 3 | 2.37 - 2.37 | 1.00 - 4.00 | 100.0% |
| adverse_event_type | 1,182 | 1 | 4.20 - 4.20 | 1.00 - 8.00 | 100.0% |
| study_drug_related | 1,182 | 1 | 1.92 - 1.92 | 1.00 - 8.00 | 100.0% |
| total_adverse_events | 1,182 | 1 | 3.70 - 3.70 | 1.00 - 19.00 | 100.0% |
| serious_adverse_event | 1,182 | 1 | 0.00 - 0.00 | 0.00 - 1.00 | 100.0% |
| days_in_study | 1,176 | 1 | 855.07 - 855.07 | 19.00 - 2295.00 | 99.5% |
| CD4 cell count - enrollment | 1,108 | 1 | 402.63 - 402.63 | 2.00 - 9999.00 | 43.5% |
| SYSTOLIC BLOOD PRESSURE | 1,070 | 1 | 118.28 - 118.28 | 78.00 - 180.00 | 99.8% |
| DIASTOLIC BLOOD PRESSURE | 1,070 | 1 | 72.92 - 72.92 | 40.00 - 123.00 | 99.8% |
| HEART RATE | 1,069 | 1 | 80.50 - 80.50 | 50.00 - 160.00 | 99.7% |
| ORAL TEMPERATURE | 1,068 | 1 | 36.52 - 36.52 | 34.20 - 39.90 | 99.6% |
| HIV Viral Load | 1,067 | 1 | 248208.77 - 248208.77 | 418.00 - 10000001.00 | 99.5% |
| hip circumference | 998 | 1 | 106.37 - 106.37 | 0.00 - 173.87 | 98.5% |
| visit_timepoint | 784 | 1 | 8.84 - 8.84 | 0.00 - 24.00 | 100.0% |
| study_week | 585 | 5 | 0.00 - 0.00 | 0.00 - 0.00 | 100.0% |
| CD4 cell count - at ART start | 497 | 1 | 333.30 - 333.30 | 0.00 - 9999.00 | 19.5% |
| Height (cm) | 451 | 1 | 160.83 - 160.83 | 142.00 - 184.00 | 100.0% |
| Weight (kg) | 451 | 1 | 64.67 - 64.67 | 35.30 - 154.00 | 100.0% |
| Creatinine clearance (mL/min) | 451 | 1 | 106.78 - 106.78 | 71.00 - 174.00 | 100.0% |
| HIV viral load | 408 | 1 | 12477736.58 - 12477736.58 | 0.00 - 99999999.00 | 16.0% |
| visit_number | 401 | 1 | 201.00 - 201.00 | 201.00 - 201.00 | 100.0% |
| enrollment_year | 401 | 1 | 2015.61 - 2015.61 | 2015.00 - 2016.00 | 100.0% |
| hemoglobin | 401 | 1 | 15.25 - 15.25 | 7.30 - 19.30 | 100.0% |
| hematocrit | 401 | 1 | 45.85 - 45.85 | 25.50 - 57.80 | 100.0% |
| mean corpuscular volume | 401 | 1 | 88.12 - 88.12 | 58.00 - 107.00 | 100.0% |
| white blood cell count | 401 | 1 | 5.59 - 5.59 | 2.20 - 14.90 | 100.0% |
| neutrophil percentage | 401 | 1 | 2891.66 - 2891.66 | 780.00 - 11234.00 | 100.0% |
| lymphocyte percentage | 401 | 1 | 2067.56 - 2067.56 | 720.00 - 4310.00 | 100.0% |
| monocyte percentage | 401 | 1 | 362.63 - 362.63 | 52.00 - 1780.00 | 100.0% |
| eosinophil percentage | 401 | 1 | 212.67 - 212.67 | 0.00 - 1910.00 | 100.0% |
| basophil percentage | 401 | 1 | 58.48 - 58.48 | 0.00 - 980.00 | 100.0% |
| total_bilirubin | 401 | 1 | 0.62 - 0.62 | 0.10 - 5.50 | 100.0% |
| phosphorus | 401 | 1 | 3.44 - 3.44 | 0.30 - 12.10 | 100.0% |
| platelet count | 400 | 1 | 251.93 - 251.93 | 63.00 - 2582.00 | 99.8% |
| age_first_sex | 396 | 1 | 18.29 - 18.29 | 7.00 - 38.00 | 98.8% |
| CD4 cell count - latest | 316 | 1 | 456.76 - 456.76 | 6.00 - 9999.00 | 12.4% |
| CD4 cell count - lowest | 316 | 1 | 342.16 - 342.16 | 5.00 - 936.00 | 12.4% |
| last_weight_recorded | 285 | 1 | 79.61 - 79.61 | 43.00 - 150.00 | 51.2% |
| last_height_recorded | 280 | 1 | 1.63 - 1.63 | 1.31 - 1.91 | 50.3% |
| Hemoglobin (g/dL) | 267 | 4 | 11.78 - 12.00 | 8.00 - 15.00 | 100.0% |
| Hematocrit (%) | 267 | 4 | 27.40 - 29.17 | 0.00 - 58.00 | 100.0% |
| White blood cell count (×10³/µL) | 267 | 4 | 4.23 - 4.66 | 1.60 - 11.00 | 100.0% |
| Platelet count (×10³/µL) | 267 | 4 | 3.00 - 3.00 | 3.00 - 3.00 | 100.0% |
| ALT (U/L) | 267 | 4 | 1.00 - 1.12 | 1.00 - 2.00 | 100.0% |
| AST (U/L) | 255 | 4 | 58.61 - 59.92 | 11.10 - 84.60 | 96.1% |
| Creatinine (mg/dL) | 148 | 3 | 0.65 - 0.65 | 0.40 - 0.90 | 32.8% |
| creatinine | 104 | 1 | 0.79 - 0.79 | 0.40 - 1.15 | 25.9% |
| HIV viral load - latest | 88 | 1 | 12497579.86 - 12497579.86 | 0.00 - 99999999.00 | 3.5% |
| HIV viral load (copies/mL) | 78 | 2 | 400.00 - 400.00 | 400.00 - 400.00 | 100.0% |
| neurological_assessment_available | 78 | 1 | 1.00 - 1.00 | 1.00 - 1.00 | 100.0% |
| total_follow_up_weeks | 78 | 1 | 172.72 - 172.72 | 16.00 - 212.00 | 100.0% |
| visit_date | 0 | 9 | N/A | N/A | N/A |
| province | 0 | 8 | N/A | N/A | N/A |
| CD4 cell count (cells/µL) | 0 | 2 | N/A | N/A | N/A |
| HIV viral load suppression | 0 | 2 | N/A | N/A | N/A |
| study_completion_status | 0 | 3 | N/A | N/A | N/A |
| date of birth | 0 | 1 | N/A | N/A | N/A |
| site_name | 0 | 1 | N/A | N/A | N/A |
| facility_name | 0 | 1 | N/A | N/A | N/A |
| town | 0 | 1 | N/A | N/A | N/A |
| HIV viral load status | 0 | 1 | N/A | N/A | N/A |
| date_care_entry | 0 | 1 | N/A | N/A | N/A |
| date_art_start | 0 | 1 | N/A | N/A | N/A |
| education_level | 0 | 2 | N/A | N/A | N/A |
| employment_status | 0 | 2 | N/A | N/A | N/A |
| marital_status | 0 | 2 | N/A | N/A | N/A |
| monthly_income | 0 | 2 | N/A | N/A | N/A |
| housing_type | 0 | 1 | N/A | N/A | N/A |
| medical_insurance | 0 | 1 | N/A | N/A | N/A |
| visit_name | 0 | 1 | N/A | N/A | N/A |
| diabetes mellitus | 0 | 2 | N/A | N/A | N/A |
| hypertension | 0 | 2 | N/A | N/A | N/A |
| asthma | 0 | 1 | N/A | N/A | N/A |
| covid-19 | 0 | 1 | N/A | N/A | N/A |
| obesity | 0 | 1 | N/A | N/A | N/A |
| enrollment_date | 0 | 1 | N/A | N/A | N/A |
| adverse_event_date | 0 | 1 | N/A | N/A | N/A |
| jhu_report_date | 0 | 1 | N/A | N/A | N/A |
| adverse_event_grade | 0 | 1 | N/A | N/A | N/A |
| gender_identity | 0 | 1 | N/A | N/A | N/A |
| ethnicity | 0 | 1 | N/A | N/A | N/A |
| HIV test result | 0 | 2 | N/A | N/A | N/A |
| HIV-1 test result | 0 | 1 | N/A | N/A | N/A |
| HIV-2 test result | 0 | 1 | N/A | N/A | N/A |
| urine_protein | 0 | 1 | N/A | N/A | N/A |
| urine_glucose | 0 | 1 | N/A | N/A | N/A |
| syphilis_result | 0 | 1 | N/A | N/A | N/A |
| gonorrhea_result | 0 | 1 | N/A | N/A | N/A |
| chlamydia_result | 0 | 1 | N/A | N/A | N/A |
| hepatitis_A | 0 | 1 | N/A | N/A | N/A |
| hepatitis_B | 0 | 1 | N/A | N/A | N/A |
| religion | 0 | 1 | N/A | N/A | N/A |
| household_size | 0 | 1 | N/A | N/A | N/A |
| sexual_identity | 0 | 1 | N/A | N/A | N/A |
| sexual_attraction | 0 | 1 | N/A | N/A | N/A |
| gender_expression | 0 | 1 | N/A | N/A | N/A |
| sexual_orientation_disclosure | 0 | 1 | N/A | N/A | N/A |
| stigma_harassment | 0 | 1 | N/A | N/A | N/A |
| stigma_violence | 0 | 1 | N/A | N/A | N/A |
| stigma_discrimination | 0 | 1 | N/A | N/A | N/A |
| stigma_healthcare | 0 | 1 | N/A | N/A | N/A |
| stigma_avoidance | 0 | 1 | N/A | N/A | N/A |
| social_support_money | 0 | 1 | N/A | N/A | N/A |
| social_support_clinic | 0 | 1 | N/A | N/A | N/A |
| social_support_talk | 0 | 1 | N/A | N/A | N/A |
| social_support_food | 0 | 1 | N/A | N/A | N/A |
| circumcision_status | 0 | 1 | N/A | N/A | N/A |
| circumcision_type | 0 | 1 | N/A | N/A | N/A |
| enrollment_completed | 0 | 1 | N/A | N/A | N/A |
| blood_collection | 0 | 1 | N/A | N/A | N/A |
| urine_collection | 0 | 1 | N/A | N/A | N/A |
| swab_collection | 0 | 1 | N/A | N/A | N/A |
| hiv_testing_done | 0 | 1 | N/A | N/A | N/A |
| Syphilis test result | 0 | 1 | N/A | N/A | N/A |
| Gonorrhea test result | 0 | 1 | N/A | N/A | N/A |
| Chlamydia test result | 0 | 1 | N/A | N/A | N/A |
| Trichomonas test result | 0 | 1 | N/A | N/A | N/A |
| vaccination_date | 0 | 1 | N/A | N/A | N/A |
| vaccination_site | 0 | 1 | N/A | N/A | N/A |
| vaccination_route | 0 | 1 | N/A | N/A | N/A |
| HIV status | 0 | 1 | N/A | N/A | N/A |
| Hyperlipidaemia | 0 | 1 | N/A | N/A | N/A |
| cohort | 0 | 1 | N/A | N/A | N/A |
| HIV ART Status | 0 | 1 | N/A | N/A | N/A |
| TRANSFERRIN | 0 | 1 | N/A | N/A | N/A |
| dyslipidemia | 0 | 1 | N/A | N/A | N/A |
| tuberculosis | 0 | 1 | N/A | N/A | N/A |
Blood Chemistry (17 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| FASTING HDL | 3,035 | 4 | 1.12 - 16.88 | 0.10 - 89.32 | 96.2% |
| FASTING LDL | 3,034 | 4 | 1.68 - 40.02 | 0.00 - 190.14 | 96.2% |
| FASTING TOTAL CHOLESTEROL | 3,034 | 4 | 4.12 - 65.87 | 1.12 - 251.93 | 96.2% |
| FASTING GLUCOSE | 2,750 | 4 | 4.94 - 36.35 | 0.95 - 295.00 | 71.9% |
| ALBUMIN | 1,986 | 3 | 37.61 - 41.69 | 1.70 - 60.00 | 63.6% |
| AST | 1,737 | 3 | 22.83 - 32.12 | 10.00 - 326.00 | 98.7% |
| ALT | 1,737 | 3 | 20.81 - 25.06 | 5.00 - 465.00 | 98.7% |
| CREATININE | 1,335 | 2 | 38.40 - 63.78 | 0.42 - 237.00 | 98.0% |
| POTASSIUM | 1,223 | 2 | 4.30 - 4.82 | 1.05 - 6.60 | 98.1% |
| ALKALINE PHOSPHATASE | 1,031 | 2 | 81.82 - 81.82 | 30.00 - 946.00 | 48.1% |
| SODIUM | 1,031 | 1 | 136.41 - 136.41 | 122.00 - 147.00 | 96.2% |
| TOTAL BILIRUBIN | 1,031 | 1 | 3.61 - 3.61 | 0.10 - 77.40 | 96.2% |
| FASTING TRIGLYCERIDES | 986 | 1 | 1.04 - 1.04 | 0.22 - 10.42 | 97.3% |
| TOTAL PROTEIN | 937 | 2 | 54.94 - 54.94 | 12.09 - 261.25 | 46.2% |
| creatinine clearance | 305 | 1 | 128.88 - 128.88 | 40.00 - 243.00 | 100.0% |
| CALCIUM | 1 | 1 | 2.31 - 2.31 | 2.31 - 2.31 | 0.3% |
| LDH | 0 | 1 | N/A | N/A | 0.0% |
Physical Examination (7 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| weight | 5,669 | 7 | 63.20 - 79.64 | 34.00 - 200.00 | 85.0% |
| systolic blood pressure | 4,002 | 4 | 118.50 - 132.30 | 81.00 - 258.50 | 92.8% |
| diastolic blood pressure | 4,002 | 4 | 75.20 - 88.40 | 40.00 - 150.00 | 92.8% |
| oral temperature | 2,481 | 3 | 36.25 - 36.49 | 34.10 - 37.70 | 75.3% |
| respiration rate | 1,424 | 3 | 16.56 - 17.94 | 12.00 - 22.00 | 75.2% |
| heart rate | 355 | 2 | 70.23 - 78.00 | 50.00 - 110.00 | 63.0% |
| Other measures of obesity | 354 | 2 | 26.53 - 27.91 | 17.51 - 47.39 | 62.9% |
Static Variables (7 variables)
| Variable | Total N | Studies | Mean Range | Overall Range | Avg Completeness |
|---|---|---|---|---|---|
| Age (at enrolment) | 8,851 | 11 | 20.84 - 53.51 | 15.00 - 76.00 | 97.6% |
| date | 7,191 | 8 | N/A | N/A | 99.3% |
| Height | 5,666 | 7 | 1.27 - 167.00 | 0.01 - 197.00 | 84.9% |
| Sex | 5,067 | 12 | N/A | N/A | 99.7% |
| Race | 4,055 | 4 | N/A | N/A | 99.6% |
| Country | 497 | 11 | N/A | N/A | 100.0% |
| Clinical Study ID | 192 | 1 | N/A | N/A | 100.0% |
3. Biomarker Coverage Matrix Across Studies
This matrix shows which studies have which biomarkers, with completeness percentages. Use this to identify data gaps.
| Biomarker | Category | Total N | ACTG_015 | ACTG_016 | ACTG_017 | ACTG_018 | ACTG_019 | ACTG_021 | Aurum_009 | DPHRU_013 | DPHRU_053 | EZIN_025 | Ezin_002 | IMPAACT_010 | JHSPH_005 | SCHARP_004 | SCHARP_006 | VIDA_007 | VIDA_008 | WRHI_001 | WRHI_003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALBUMIN | blood chemistry | 1,986 | - | - | - | - | - | - | - | - | 94% | - | - | - | - | - | - | - | - | 96% | 0% |
| ALKALINE PHOSPHATASE | blood chemistry | 1,031 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 0% |
| ALT | blood chemistry | 1,737 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | 96% | 100% |
| ALT (U/L) | Uncategorized | 267 | 100% | 100% | - | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| AST | blood chemistry | 1,737 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | 96% | 100% |
| AST (U/L) | Uncategorized | 255 | 100% | 100% | - | 0% | 88% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Age (at enrolment) | static variables | 8,851 | 0% | 0% | - | - | - | - | 100% | 98% | 100% | - | - | - | - | 100% | 100% | 82% | 99% | 100% | 100% |
| Antiretroviral Therapy Status | HIV | 305 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% |
| BASOPHILS | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| BMI | Uncategorized | 3,387 | - | - | - | - | - | - | - | 98% | 99% | - | - | - | - | - | - | - | 97% | 100% | - |
| CALCIUM | blood chemistry | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% |
| CD4 Count | HIV | 1,367 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | 98% |
| CD4 cell count | Uncategorized | 2,273 | - | - | - | - | - | - | 89% | - | - | - | - | - | - | - | - | - | - | - | - |
| CD4 cell count (cells/µL) | Uncategorized | 0 | 0% | 0% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CD4 cell count - at ART start | Uncategorized | 497 | - | - | - | - | - | - | 19% | - | - | - | - | - | - | - | - | - | - | - | - |
| CD4 cell count - enrollment | Uncategorized | 1,108 | - | - | - | - | - | - | 43% | - | - | - | - | - | - | - | - | - | - | - | - |
| CD4 cell count - latest | Uncategorized | 316 | - | - | - | - | - | - | 12% | - | - | - | - | - | - | - | - | - | - | - | - |
| CD4 cell count - lowest | Uncategorized | 316 | - | - | - | - | - | - | 12% | - | - | - | - | - | - | - | - | - | - | - | - |
| CREATININE | blood chemistry | 1,335 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 100% |
| Chlamydia test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - |
| Clinical Study ID | static variables | 192 | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - | - | - | - |
| Country | static variables | 497 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | - | 100% | - | - | - | 0% | 0% | - | - | - | 100% |
| Creatinine (mg/dL) | Uncategorized | 148 | 0% | 0% | - | - | - | - | - | - | - | - | - | - | - | - | 33% | - | - | - | - |
| Creatinine clearance (mL/min) | Uncategorized | 451 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - |
| DIASTOLIC BLOOD PRESSURE | Uncategorized | 1,070 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - |
| EOSINOPHILS | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| Erythrocytes | Haematology | 302 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| FASTING GLUCOSE | blood chemistry | 2,750 | - | - | - | - | - | - | - | 96% | 98% | - | - | - | - | - | - | - | - | 94% | 0% |
| FASTING HDL | blood chemistry | 3,035 | - | - | - | - | - | - | - | 92% | 97% | - | - | - | - | - | - | - | - | 95% | 100% |
| FASTING LDL | blood chemistry | 3,034 | - | - | - | - | - | - | - | 92% | 97% | - | - | - | - | - | - | - | - | 95% | 100% |
| FASTING TOTAL CHOLESTEROL | blood chemistry | 3,034 | - | - | - | - | - | - | - | 92% | 97% | - | - | - | - | - | - | - | - | 95% | 100% |
| FASTING TRIGLYCERIDES | blood chemistry | 986 | - | - | - | - | - | - | - | - | 97% | - | - | - | - | - | - | - | - | - | - |
| Gonorrhea test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - |
| HEART RATE | Uncategorized | 1,069 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - |
| HEMATOCRIT | Haematology | 1,066 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | - |
| HEMOGLOBIN | Haematology | 1,367 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | 99% |
| HIV ART Status | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - |
| HIV Viral Load | Uncategorized | 1,067 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - |
| HIV status | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - |
| HIV test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | 0% | - | - | - | - |
| HIV viral load | Uncategorized | 408 | - | - | - | - | - | - | 16% | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV viral load (copies/mL) | Uncategorized | 78 | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV viral load - latest | Uncategorized | 88 | - | - | - | - | - | - | 3% | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV viral load status | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV viral load suppression | Uncategorized | 0 | 0% | 0% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| HIV-1 test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| HIV-2 test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| Height | static variables | 5,666 | - | - | - | - | - | - | - | 72% | 99% | 26% | - | - | - | - | - | 100% | 97% | 100% | 100% |
| Height (cm) | Uncategorized | 451 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - |
| Hematocrit (%) | Uncategorized | 267 | 100% | 100% | - | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Hemoglobin (g/dL) | Uncategorized | 267 | 100% | 100% | - | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Hyperlipidaemia | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - |
| LDH | blood chemistry | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% |
| LYMPHOCYTES | Haematology | 1,367 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | 99% |
| MCV (MEAN CELL VOLUME) | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| MONOCYTES | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| Mean Cell Haemoglobin | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| Mean Cell Haemoglobin Concentration | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| NEUTROPHILS | Haematology | 1,367 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | 99% |
| ORAL TEMPERATURE | Uncategorized | 1,068 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - |
| Other measures of obesity | physical examination | 354 | - | - | - | - | - | - | - | - | - | 26% | - | - | - | - | - | - | - | - | 100% |
| PCR - HIV Viral Load Roche | HIV | 305 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% |
| PLATELET COUNT | Haematology | 1,351 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98% | 99% |
| POTASSIUM | blood chemistry | 1,223 | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - | - | 96% | - |
| Platelet count (×10³/µL) | Uncategorized | 267 | 100% | 100% | - | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| RDW | Haematology | 301 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% |
| Race | static variables | 4,055 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | 99% | 100% | 100% |
| SODIUM | blood chemistry | 1,031 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | - |
| SYSTOLIC BLOOD PRESSURE | Uncategorized | 1,070 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - |
| Sex | static variables | 5,067 | 0% | 0% | - | 0% | 0% | - | 0% | - | 100% | - | - | - | - | 0% | 0% | 100% | 99% | 100% | 100% |
| Syphilis test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - |
| TOTAL BILIRUBIN | blood chemistry | 1,031 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | - |
| TOTAL PROTEIN | blood chemistry | 937 | - | - | - | - | - | - | - | - | 92% | - | - | - | - | - | - | - | - | - | 0% |
| TRANSFERRIN | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% |
| Trichomonas test result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - |
| WBC | Haematology | 1,367 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | 99% |
| Weight (kg) | Uncategorized | 451 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - |
| White blood cell count (×10³/µL) | Uncategorized | 267 | 100% | 100% | - | 0% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| adverse_event_date | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - |
| adverse_event_grade | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - |
| adverse_event_type | Uncategorized | 1,182 | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - |
| age_first_sex | Uncategorized | 396 | - | - | - | - | - | - | - | - | - | - | - | - | - | 99% | - | - | - | - | - |
| asthma | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - |
| basophil percentage | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| blood_collection | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| bmi | Uncategorized | 2,128 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - |
| chlamydia_result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| circumcision_status | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| circumcision_type | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| cohort | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - |
| covid-19 | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - |
| creatinine | Uncategorized | 104 | - | - | - | - | - | - | - | - | - | - | - | - | - | 26% | - | - | - | - | - |
| creatinine clearance | blood chemistry | 305 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% |
| date | static variables | 7,191 | - | - | - | - | - | - | - | 98% | 99% | 100% | - | - | 100% | - | - | 100% | 99% | 100% | 100% |
| date of birth | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| date_art_start | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| date_care_entry | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| days_in_study | Uncategorized | 1,176 | - | - | - | - | - | - | - | - | - | - | - | - | 99% | - | - | - | - | - | - |
| diabetes mellitus | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | 0% |
| diastolic blood pressure | physical examination | 4,002 | - | - | - | - | - | - | - | 72% | 99% | - | - | - | - | - | - | 100% | - | - | 100% |
| dyslipidemia | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% |
| education_level | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | 0% | - | - | - | - | - |
| employment_status | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | 0% | - | - | - | - | - |
| enrollment_completed | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| enrollment_date | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - |
| enrollment_year | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| eosinophil percentage | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| ethnicity | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| facility_name | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| gender_expression | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| gender_identity | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| gonorrhea_result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| heart rate | physical examination | 355 | - | - | - | - | - | - | - | - | - | 26% | - | - | - | - | - | - | - | - | 100% |
| heat_completeness | Uncategorized | 10,180 | - | - | - | - | - | - | 100% | 100% | 100% | 100% | - | - | 100% | 100% | - | 100% | 100% | 100% | 100% |
| hematocrit | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| hemoglobin | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| hepatitis_A | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| hepatitis_B | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| hip circumference | Uncategorized | 998 | - | - | - | - | - | - | - | - | 99% | - | - | - | - | - | - | - | - | - | - |
| hiv_testing_done | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| household_size | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| housing_type | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| hypertension | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | 0% |
| jhu_report_date | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - |
| last_height_recorded | Uncategorized | 280 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50% | - | - |
| last_weight_recorded | Uncategorized | 285 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51% | - | - |
| lymphocyte percentage | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| marital_status | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | 0% | - | - | - | - | - |
| mean corpuscular volume | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| medical_insurance | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| monocyte percentage | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| monthly_income | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | 0% | - | - | - | - | - |
| neurological_assessment_available | Uncategorized | 78 | - | - | - | - | - | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| neutrophil percentage | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| obesity | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - |
| oral temperature | physical examination | 2,481 | - | - | - | - | - | - | - | - | - | 26% | - | - | - | - | - | 100% | - | - | 100% |
| oxygen_saturation | Uncategorized | 2,127 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - |
| phosphorus | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| platelet count | Uncategorized | 400 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| province | Uncategorized | 0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | - | - | - | - | - | - | 0% | - | - | - | - |
| pulse_rate | Uncategorized | 2,129 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - |
| religion | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| respiration rate | physical examination | 1,424 | - | - | - | - | - | - | - | - | - | 26% | - | - | - | - | - | - | - | 100% | 100% |
| respiratory_rate | Uncategorized | 2,123 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - |
| serious_adverse_event | Uncategorized | 1,182 | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - |
| sexual_attraction | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| sexual_identity | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| sexual_orientation_disclosure | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| site_name | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| social_support_clinic | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| social_support_food | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| social_support_money | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| social_support_talk | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| stigma_avoidance | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| stigma_discrimination | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| stigma_harassment | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| stigma_healthcare | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| stigma_violence | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| study_completion_status | Uncategorized | 0 | 0% | 0% | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| study_drug_related | Uncategorized | 1,182 | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - |
| study_week | Uncategorized | 585 | 100% | 100% | - | 100% | 100% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| swab_collection | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| syphilis_result | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| systolic blood pressure | physical examination | 4,002 | - | - | - | - | - | - | - | 72% | 99% | - | - | - | - | - | - | 100% | - | - | 100% |
| total_adverse_events | Uncategorized | 1,182 | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - |
| total_bilirubin | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| total_follow_up_weeks | Uncategorized | 78 | - | - | - | - | - | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| town | Uncategorized | 0 | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| treatment_arm | Uncategorized | 1,182 | 0% | 0% | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - |
| tuberculosis | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% |
| urine_collection | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| urine_glucose | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| urine_protein | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - | - | - |
| vaccination_date | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - |
| vaccination_route | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - |
| vaccination_site | Uncategorized | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0% | - | - | - |
| visit_date | Uncategorized | 0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | - | - | - | - | - | 0% | 0% | - | - | - | - |
| visit_name | Uncategorized | 0 | - | - | - | - | - | - | - | 0% | - | - | - | - | - | - | - | - | - | - | - |
| visit_number | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
| visit_timepoint | Uncategorized | 784 | - | - | - | - | - | - | - | 100% | - | - | - | - | - | - | - | - | - | - | - |
| waist circumference | Uncategorized | 1,576 | - | - | - | - | - | - | - | 72% | 100% | - | - | - | - | - | - | - | - | - | - |
| weight | physical examination | 5,669 | - | - | - | - | - | - | - | 72% | 99% | 26% | - | - | - | - | - | 100% | 98% | 100% | 100% |
| white blood cell count | Uncategorized | 401 | - | - | - | - | - | - | - | - | - | - | - | - | - | 100% | - | - | - | - | - |
4. Individual Study Profiles with Visualizations
Complete profiles for each study with embedded distribution plots.
JHB_ACTG_015
Full Name: ACTG_5208_Nevirapine_Lopinavir_Trial
Study Type: Randomized Clinical Trial
Records: 177
Participants: 87
Variables Harmonized: 18
Distribution Plots
Jhb Actg 015 All Distributions
Jhb Actg 015 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Actg 015 Categorical All Page1
Jhb Actg 015 Categorical All Page2
Jhb Actg 015 Categorical All Page3
JHB_ACTG_016
Full Name: ACTG_5221_HIV_TB_Coinfection_Trial
Study Type: Randomized Clinical Trial
Records: 78
Participants: 76
Variables Harmonized: 19
Distribution Plots
Jhb Actg 016 All Distributions
Jhb Actg 016 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Actg 016 Categorical All Page1
Jhb Actg 016 Categorical All Page2
Jhb Actg 016 Categorical All Page3
JHB_ACTG_017
Full Name: Unknown
Study Type: Unknown
Records: 0
Participants: 0
Variables Harmonized: 7
Distribution Plots
No distribution plots available for this study.
Missing Data Analysis
Categorical Variables
Jhb Actg 017 Categorical All
JHB_ACTG_018
Full Name: ACTG_5271_Neurological_Study
Study Type: Clinical Trial
Records: 0
Participants: 0
Variables Harmonized: 9
Distribution Plots
Jhb Actg 018 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Actg 018 Categorical All Page1
Jhb Actg 018 Categorical All Page2
JHB_ACTG_019
Full Name: ACTG_5175_Treatment_Study
Study Type: Clinical Trial
Records: 0
Participants: 0
Variables Harmonized: 15
Distribution Plots
Jhb Actg 019 All Distributions
Jhb Actg 019 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Actg 019 Categorical All Page1
Jhb Actg 019 Categorical All Page2
JHB_ACTG_021
Full Name: ACTG_5199_International_Neurological_Study
Study Type: Neurological Assessment
Records: 671
Participants: 78
Variables Harmonized: 12
Distribution Plots
Jhb Actg 021 All Distributions
Missing Data Analysis
Categorical Variables
Jhb Actg 021 Categorical All
JHB_Aurum_009
Full Name: Tholimpilo_HIV_Linkage_Study
Study Type: Hiv Linkage Care Program
Description: Multi-site HIV testing and linkage to care program evaluation
Records: 2,930
Participants: 2,551
Variables Harmonized: 4
Distribution Plots
Jhb Aurum 009 All Distributions
Jhb Aurum 009 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Aurum 009 Categorical All Page1
Jhb Aurum 009 Categorical All Page2
Jhb Aurum 009 Categorical All Page3
JHB_DPHRU_013
Full Name: WBS_Longitudinal
Study Type: Unknown
Records: 784
Participants: 0
Variables Harmonized: 11
Distribution Plots
Jhb Dphru 013 All Distributions
Jhb Dphru 013 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Dphru 013 Categorical All Page1
Jhb Dphru 013 Categorical All Page2
JHB_DPHRU_053
Full Name: MASC
Study Type: Unknown
Records: 1,013
Participants: 0
Variables Harmonized: 15
Distribution Plots
Jhb Dphru 053 All Distributions Page1
Jhb Dphru 053 All Distributions Page2
Jhb Dphru 053 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Dphru 053 Categorical All
JHB_EZIN_025
Full Name: EZIN025_COVID19_Treatment_Trial
Study Type: Covid19 Randomized Trial
Description: COVID-19 treatment trial with 5 treatment arms
Records: 192
Participants: 192
Variables Harmonized: 11
Distribution Plots
Jhb Ezin 025 All Distributions
Jhb Ezin 025 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Ezin 025 Categorical All Page1
Jhb Ezin 025 Categorical All Page2
JHB_Ezin_002
Distribution Plots
No distribution plots available for this study.
JHB_IMPAACT_010
Distribution Plots
No distribution plots available for this study.
JHB_JHSPH_005
Full Name: Tuberculosis_Prevention_Trial
Study Type: Adverse Events Clinical Trial
Description: Limited HEAT mapping due to adverse events focus
Records: 1,182
Participants: 0
Variables Harmonized: 2
Distribution Plots
No distribution plots available for this study.
Missing Data Analysis
Categorical Variables
Jhb Jhsph 005 Categorical All Page1
Jhb Jhsph 005 Categorical All Page2
JHB_SCHARP_004
Full Name: HPTN_075_MSM_Prevention_Feasibility
Study Type: Hiv Prevention Feasibility
Description: Comprehensive MSM HIV prevention feasibility study with extensive biomarker and behavioral data
Records: 401
Participants: 401
Variables Harmonized: 6
Distribution Plots
Jhb Scharp 004 All Distributions Page1
Jhb Scharp 004 All Distributions Page2
Jhb Scharp 004 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Scharp 004 Categorical All Page1
Jhb Scharp 004 Categorical All Page2
Jhb Scharp 004 Categorical All Page3
Jhb Scharp 004 Categorical All Page4
Jhb Scharp 004 Categorical All Page5
Jhb Scharp 004 Categorical All Page6
Jhb Scharp 004 Categorical All Page7
Jhb Scharp 004 Categorical All Page8
JHB_SCHARP_006
Full Name: HPTN_082_PrEP_Young_Women
Study Type: Prep Feasibility
Records: 451
Participants: 451
Variables Harmonized: 19
Distribution Plots
Jhb Scharp 006 All Distributions
Jhb Scharp 006 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Scharp 006 Categorical All Page1
Jhb Scharp 006 Categorical All Page2
JHB_VIDA_007
Full Name: COVID_Vaccine_ChAdOx1_AstraZeneca
Study Type: Covid Vaccine Clinical Trial
Description: Multi-CSV integration with demographics, vitals, and vaccination data
Records: 2,129
Participants: 0
Variables Harmonized: 10
Distribution Plots
Jhb Vida 007 All Distributions
Jhb Vida 007 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Vida 007 Categorical All Page1
Jhb Vida 007 Categorical All Page2
JHB_VIDA_008
Full Name: COVID_Healthcare_Worker_Study
Study Type: Covid Hcw Longitudinal Cohort
Description: Multi-cohort healthcare worker study with baseline demographics and clinical measurements
Records: 557
Participants: 552
Variables Harmonized: 7
Distribution Plots
Jhb Vida 008 All Distributions
Jhb Vida 008 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Vida 008 Categorical All Page1
Jhb Vida 008 Categorical All Page2
JHB_WRHI_001
Full Name: WRHI001_Stavudine_vs_Tenofovir
Study Type: Hiv Art Randomized Trial
Description: HIV antiretroviral therapy clinical trial comparing stavudine vs tenofovir regimens
Records: 1,072
Participants: 1,072
Variables Harmonized: 27
Distribution Plots
Jhb Wrhi 001 All Distributions Page1
Jhb Wrhi 001 All Distributions Page2
Jhb Wrhi 001 All Distributions Page3
Jhb Wrhi 001 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Wrhi 001 Categorical All Page1
Jhb Wrhi 001 Categorical All Page2
JHB_WRHI_003
Full Name: WRHI003_Darunavir_vs_Lopinavir
Study Type: Hiv Art Randomized Trial
Description: HIV antiretroviral therapy clinical trial comparing low-dose darunavir vs lopinavir regimens
Records: 305
Participants: 300
Variables Harmonized: 43
Distribution Plots
Jhb Wrhi 003 All Distributions Page1
Jhb Wrhi 003 All Distributions Page2
Jhb Wrhi 003 All Distributions Page3
Jhb Wrhi 003 Biomarker Distributions
Missing Data Analysis
Categorical Variables
Jhb Wrhi 003 Categorical All Page1
Jhb Wrhi 003 Categorical All Page2
Jhb Wrhi 003 Categorical All Page3
Jhb Wrhi 003 Categorical All Page4
5. Data Gap Analysis and Recommendations
Biomarkers with Limited Coverage (< 30% of studies)
| Biomarker | Available In | Missing From |
|---|---|---|
| neurological_assessment_available | 1 studies | 18 studies |
| total_follow_up_weeks | 1 studies | 18 studies |
| date of birth | 1 studies | 18 studies |
| site_name | 1 studies | 18 studies |
| facility_name | 1 studies | 18 studies |
| town | 1 studies | 18 studies |
| CD4 cell count | 1 studies | 18 studies |
| CD4 cell count - enrollment | 1 studies | 18 studies |
| CD4 cell count - latest | 1 studies | 18 studies |
| CD4 cell count - lowest | 1 studies | 18 studies |
| CD4 cell count - at ART start | 1 studies | 18 studies |
| HIV viral load | 1 studies | 18 studies |
| HIV viral load - latest | 1 studies | 18 studies |
| HIV viral load status | 1 studies | 18 studies |
| date_care_entry | 1 studies | 18 studies |
| date_art_start | 1 studies | 18 studies |
| housing_type | 1 studies | 18 studies |
| medical_insurance | 1 studies | 18 studies |
| visit_timepoint | 1 studies | 18 studies |
| visit_name | 1 studies | 18 studies |
| FASTING TRIGLYCERIDES | 1 studies | 18 studies |
| hip circumference | 1 studies | 18 studies |
| Clinical Study ID | 1 studies | 18 studies |
| asthma | 1 studies | 18 studies |
| covid-19 | 1 studies | 18 studies |
| obesity | 1 studies | 18 studies |
| enrollment_date | 1 studies | 18 studies |
| adverse_event_date | 1 studies | 18 studies |
| jhu_report_date | 1 studies | 18 studies |
| adverse_event_type | 1 studies | 18 studies |
| adverse_event_grade | 1 studies | 18 studies |
| study_drug_related | 1 studies | 18 studies |
| total_adverse_events | 1 studies | 18 studies |
| days_in_study | 1 studies | 18 studies |
| serious_adverse_event | 1 studies | 18 studies |
| visit_number | 1 studies | 18 studies |
| gender_identity | 1 studies | 18 studies |
| enrollment_year | 1 studies | 18 studies |
| ethnicity | 1 studies | 18 studies |
| HIV-1 test result | 1 studies | 18 studies |
| HIV-2 test result | 1 studies | 18 studies |
| hemoglobin | 1 studies | 18 studies |
| hematocrit | 1 studies | 18 studies |
| mean corpuscular volume | 1 studies | 18 studies |
| platelet count | 1 studies | 18 studies |
| white blood cell count | 1 studies | 18 studies |
| neutrophil percentage | 1 studies | 18 studies |
| lymphocyte percentage | 1 studies | 18 studies |
| monocyte percentage | 1 studies | 18 studies |
| eosinophil percentage | 1 studies | 18 studies |
| basophil percentage | 1 studies | 18 studies |
| creatinine | 1 studies | 18 studies |
| total_bilirubin | 1 studies | 18 studies |
| phosphorus | 1 studies | 18 studies |
| urine_protein | 1 studies | 18 studies |
| urine_glucose | 1 studies | 18 studies |
| syphilis_result | 1 studies | 18 studies |
| gonorrhea_result | 1 studies | 18 studies |
| chlamydia_result | 1 studies | 18 studies |
| hepatitis_A | 1 studies | 18 studies |
| hepatitis_B | 1 studies | 18 studies |
| religion | 1 studies | 18 studies |
| household_size | 1 studies | 18 studies |
| sexual_identity | 1 studies | 18 studies |
| sexual_attraction | 1 studies | 18 studies |
| gender_expression | 1 studies | 18 studies |
| sexual_orientation_disclosure | 1 studies | 18 studies |
| stigma_harassment | 1 studies | 18 studies |
| stigma_violence | 1 studies | 18 studies |
| stigma_discrimination | 1 studies | 18 studies |
| stigma_healthcare | 1 studies | 18 studies |
| stigma_avoidance | 1 studies | 18 studies |
| social_support_money | 1 studies | 18 studies |
| social_support_clinic | 1 studies | 18 studies |
| social_support_talk | 1 studies | 18 studies |
| social_support_food | 1 studies | 18 studies |
| age_first_sex | 1 studies | 18 studies |
| circumcision_status | 1 studies | 18 studies |
| circumcision_type | 1 studies | 18 studies |
| enrollment_completed | 1 studies | 18 studies |
| blood_collection | 1 studies | 18 studies |
| urine_collection | 1 studies | 18 studies |
| swab_collection | 1 studies | 18 studies |
| hiv_testing_done | 1 studies | 18 studies |
| Height (cm) | 1 studies | 18 studies |
| Weight (kg) | 1 studies | 18 studies |
| Creatinine clearance (mL/min) | 1 studies | 18 studies |
| Syphilis test result | 1 studies | 18 studies |
| Gonorrhea test result | 1 studies | 18 studies |
| Chlamydia test result | 1 studies | 18 studies |
| Trichomonas test result | 1 studies | 18 studies |
| pulse_rate | 1 studies | 18 studies |
| respiratory_rate | 1 studies | 18 studies |
| oxygen_saturation | 1 studies | 18 studies |
| bmi | 1 studies | 18 studies |
| vaccination_date | 1 studies | 18 studies |
| vaccination_site | 1 studies | 18 studies |
| vaccination_route | 1 studies | 18 studies |
| last_weight_recorded | 1 studies | 18 studies |
| last_height_recorded | 1 studies | 18 studies |
| HIV status | 1 studies | 18 studies |
| Hyperlipidaemia | 1 studies | 18 studies |
| cohort | 1 studies | 18 studies |
| SODIUM | 1 studies | 18 studies |
| TOTAL BILIRUBIN | 1 studies | 18 studies |
| HEMATOCRIT | 1 studies | 18 studies |
| HIV Viral Load | 1 studies | 18 studies |
| HIV ART Status | 1 studies | 18 studies |
| SYSTOLIC BLOOD PRESSURE | 1 studies | 18 studies |
| DIASTOLIC BLOOD PRESSURE | 1 studies | 18 studies |
| HEART RATE | 1 studies | 18 studies |
| ORAL TEMPERATURE | 1 studies | 18 studies |
| Antiretroviral Therapy Status | 1 studies | 18 studies |
| PCR - HIV Viral Load Roche | 1 studies | 18 studies |
| MONOCYTES | 1 studies | 18 studies |
| EOSINOPHILS | 1 studies | 18 studies |
| BASOPHILS | 1 studies | 18 studies |
| Erythrocytes | 1 studies | 18 studies |
| MCV (MEAN CELL VOLUME) | 1 studies | 18 studies |
| Mean Cell Haemoglobin | 1 studies | 18 studies |
| Mean Cell Haemoglobin Concentration | 1 studies | 18 studies |
| RDW | 1 studies | 18 studies |
| LDH | 1 studies | 18 studies |
| CALCIUM | 1 studies | 18 studies |
| creatinine clearance | 1 studies | 18 studies |
| TRANSFERRIN | 1 studies | 18 studies |
| dyslipidemia | 1 studies | 18 studies |
| tuberculosis | 1 studies | 18 studies |
| CD4 cell count (cells/µL) | 2 studies | 17 studies |
| HIV viral load (copies/mL) | 2 studies | 17 studies |
| HIV viral load suppression | 2 studies | 17 studies |
| education_level | 2 studies | 17 studies |
| employment_status | 2 studies | 17 studies |
| marital_status | 2 studies | 17 studies |
| monthly_income | 2 studies | 17 studies |
| waist circumference | 2 studies | 17 studies |
| TOTAL PROTEIN | 2 studies | 17 studies |
| heart rate | 2 studies | 17 studies |
| Other measures of obesity | 2 studies | 17 studies |
| POTASSIUM | 2 studies | 17 studies |
| diabetes mellitus | 2 studies | 17 studies |
| hypertension | 2 studies | 17 studies |
| HIV test result | 2 studies | 17 studies |
| CD4 Count | 2 studies | 17 studies |
| HEMOGLOBIN | 2 studies | 17 studies |
| CREATININE | 2 studies | 17 studies |
| ALKALINE PHOSPHATASE | 2 studies | 17 studies |
| WBC | 2 studies | 17 studies |
| PLATELET COUNT | 2 studies | 17 studies |
| NEUTROPHILS | 2 studies | 17 studies |
| LYMPHOCYTES | 2 studies | 17 studies |
| Creatinine (mg/dL) | 3 studies | 16 studies |
| treatment_arm | 3 studies | 16 studies |
| study_completion_status | 3 studies | 16 studies |
| ALBUMIN | 3 studies | 16 studies |
| oral temperature | 3 studies | 16 studies |
| respiration rate | 3 studies | 16 studies |
| AST | 3 studies | 16 studies |
| ALT | 3 studies | 16 studies |
| Hemoglobin (g/dL) | 4 studies | 15 studies |
| Hematocrit (%) | 4 studies | 15 studies |
| White blood cell count (×10³/µL) | 4 studies | 15 studies |
| Platelet count (×10³/µL) | 4 studies | 15 studies |
| AST (U/L) | 4 studies | 15 studies |
| ALT (U/L) | 4 studies | 15 studies |
| systolic blood pressure | 4 studies | 15 studies |
| diastolic blood pressure | 4 studies | 15 studies |
| FASTING GLUCOSE | 4 studies | 15 studies |
| FASTING HDL | 4 studies | 15 studies |
| FASTING LDL | 4 studies | 15 studies |
| FASTING TOTAL CHOLESTEROL | 4 studies | 15 studies |
| BMI | 4 studies | 15 studies |
| Race | 4 studies | 15 studies |
| study_week | 5 studies | 14 studies |
High-Value Biomarkers (n ≥ 1000)
These 49 biomarkers have sufficient sample size for robust analysis:
- heat_completeness: 10,180 observations across 10 studies
- Age (at enrolment): 8,851 observations across 11 studies
- date: 7,191 observations across 8 studies
- weight: 5,669 observations across 7 studies
- Height: 5,666 observations across 7 studies
- Sex: 5,067 observations across 12 studies
- Race: 4,055 observations across 4 studies
- systolic blood pressure: 4,002 observations across 4 studies
- diastolic blood pressure: 4,002 observations across 4 studies
- BMI: 3,387 observations across 4 studies
- FASTING HDL: 3,035 observations across 4 studies
- FASTING LDL: 3,034 observations across 4 studies
- FASTING TOTAL CHOLESTEROL: 3,034 observations across 4 studies
- FASTING GLUCOSE: 2,750 observations across 4 studies
- oral temperature: 2,481 observations across 3 studies
- CD4 cell count: 2,273 observations across 1 studies
- pulse_rate: 2,129 observations across 1 studies
- bmi: 2,128 observations across 1 studies
- oxygen_saturation: 2,127 observations across 1 studies
- respiratory_rate: 2,123 observations across 1 studies
- ALBUMIN: 1,986 observations across 3 studies
- AST: 1,737 observations across 3 studies
- ALT: 1,737 observations across 3 studies
- waist circumference: 1,576 observations across 2 studies
- respiration rate: 1,424 observations across 3 studies
- CD4 Count: 1,367 observations across 2 studies
- HEMOGLOBIN: 1,367 observations across 2 studies
- WBC: 1,367 observations across 2 studies
- NEUTROPHILS: 1,367 observations across 2 studies
- LYMPHOCYTES: 1,367 observations across 2 studies
- PLATELET COUNT: 1,351 observations across 2 studies
- CREATININE: 1,335 observations across 2 studies
- POTASSIUM: 1,223 observations across 2 studies
- treatment_arm: 1,182 observations across 3 studies
- adverse_event_type: 1,182 observations across 1 studies
- study_drug_related: 1,182 observations across 1 studies
- total_adverse_events: 1,182 observations across 1 studies
- serious_adverse_event: 1,182 observations across 1 studies
- days_in_study: 1,176 observations across 1 studies
- CD4 cell count - enrollment: 1,108 observations across 1 studies
- SYSTOLIC BLOOD PRESSURE: 1,070 observations across 1 studies
- DIASTOLIC BLOOD PRESSURE: 1,070 observations across 1 studies
- HEART RATE: 1,069 observations across 1 studies
- ORAL TEMPERATURE: 1,068 observations across 1 studies
- HIV Viral Load: 1,067 observations across 1 studies
- HEMATOCRIT: 1,066 observations across 1 studies
- ALKALINE PHOSPHATASE: 1,031 observations across 2 studies
- SODIUM: 1,031 observations across 1 studies
- TOTAL BILIRUBIN: 1,031 observations across 1 studies